Stocks
Supernus Pharmaceuticals, Inc.SUPN
NASDAQHealthcareBiotechnology$49.91-1.09%
Focused on developing and commercializing products for central nervous system diseases, this biopharmaceutical company markets treatments for epilepsy, migraine, and other neurological disorders. Investors monitor its pipeline for novel therapies addressing unmet needs in neurology.
Market Cap: $2.9B52W Range: $29.16 – $59.68
Congressional Interest in Supernus Pharmaceuticals, Inc. (SUPN)
3 members of Congress have disclosed 12 trades in Supernus Pharmaceuticals, Inc. (SUPN), a Healthcare company. The buy/sell breakdown shows 9 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
12
Unique Politicians
3
Buys
9
Sells
3
Who in Congress Is Trading SUPN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-12-11 | Gilbert Cisneros | buy | $1K – $15K |